Member Info for Newuncle

OMG TOC STFU YOU BORING BORING BORING KNOWITALL

Poor Tiger.....not the only one though

My point was how many times have seen others posting about PPP as an AIM listed stock now? I've lost count.....

Megan,

I should have said we all know that PPP is not listed on AIM of course

Megan,

PPP is NOT listed on AIM

How many times is it now?

LOLFL

Offski now, nothing to see here today.

From +12% to -0.7%..just like that.....bonkers moves

And back in auction again

+12% although I really do not trust these so called % changes most of the time fwiw

Moving now

EGTP,

You might be right...in Auction on hardly any volume???

Spud,

Really?

Back in the day

Colourful Australian entrepreneur David Lenigas, famed for claiming he had found 100 billion barrels of oil under Gatwick, has quit the boards of his five remaining AIM companies.

Worst affected were his African logistics firm AfriAg, which slumped 0.07p, or 28%, to 0.18p, and Mexican lithium explorer Rare Earth Minerals, 0.05p off at 0.62p. His other resignations Bacanora Minerals dropped 1.5p to 75.5p, while Inspirit Energy and Evocutis were unchanged at 0.475p and 0.89p.

Lenigas took to Twitter: “I am now off every board I was on on AIM. Don’t intend to ever go back on another one. Now I can buy shares any day I like.”

If batteries are your passion you may have noticed some stories popping up recently about an all new portable energy storage product that some are claiming will make batteries a thing of the past. Articles have been circulating that there is a new technology in town with mind blowing potential. The product is the super-capacitor.

Nice Tight Spread Now

1.35-1.38..MMs want to trade again

At last...thank you VR

Schurter and CPX Partnership and CPX Results to June 2024

Bit of a disconnect re claim that CPX need to audit Schurter imo fwiw

Steamy,

Don't waste your time arguing with uneducated ones

About OBD's New USA Partners

NEXT Bio-Research, Services continues a 23 year history in providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors. We also provide medical testing services to physicians using state-of-the-art platforms. NEXT Bio-Research Services was founded by three long standing colleagues who have worked together these past 23 years and collectively represent more than 100 years’ experience in life science technologies.

NEXT Bio-Research Services is focused in (1) clinical testing using molecular and biochemical techniques; (2) molecular genetics of pharmacogenomics and cancer; (3) contract research in drug discovery and development with private sector customers; and (4) laboratory support of human clinical trials. We function as an extension of your own laboratory in helping you to bring their products from discovery to market. Our laboratories are certified under the Clinical Laboratory Improvement Amendments (CLIA) act and our contract research services are offered individually or can be integrated to support product development from discovery to market with full regulatory support under FDA GLP Guidelines 21 CFR 58.

CIRT Has Been Approved For Clinical Use

"NYS CLEP provides an independent review of the analytical and clinical validity of any test. OBD and NEXT Molecular have been notified that the CiRT Test has passed this evaluation and been approved for clinical use."